Development and Effects of Influenza Antiviral Drugs
Open Access
- 4 February 2021
- Vol. 26 (4), 810
- https://doi.org/10.3390/molecules26040810
Abstract
Influenza virus is a highly contagious zoonotic respiratory disease that causes seasonal outbreaks each year and unpredictable pandemics occasionally with high morbidity and mortality rates, posing a great threat to public health worldwide. Besides the limited effect of vaccines, the problem is exacerbated by the lack of drugs with strong antiviral activity against all flu strains. Currently, there are two classes of antiviral drugs available that are chemosynthetic and approved against influenza A virus for prophylactic and therapeutic treatment, but the appearance of drug-resistant virus strains is a serious issue that strikes at the core of influenza control. There is therefore an urgent need to develop new antiviral drugs. Many reports have shown that the development of novel bioactive plant extracts and microbial extracts has significant advantages in influenza treatment. This paper comprehensively reviews the development and effects of chemosynthetic drugs, plant extracts, and microbial extracts with influenza antiviral activity, hoping to provide some references for novel antiviral drug design and promising alternative candidates for further anti-influenza drug development.Funding Information
- National Key Research and Development Program of China (2016YFD0500205, 2018YFD0500100)
- Natural Science Foundation of Fujian Province of China (2016J01090)
- Natural Science Foundation of China (U1805231, 32030110, 31602046)
This publication has 119 references indexed in Scilit:
- Influenza A penetrates host mucus by cleaving sialic acids with neuraminidaseVirology Journal, 2013
- Recurring Influenza B Virus Infections in SealsEmerging Infectious Diseases, 2013
- Influenza HA Subtypes Demonstrate Divergent Phenotypes for Cleavage Activation and pH of Fusion: Implications for Host Range and AdaptationPLoS Pathogens, 2013
- Influenza A Virus Entry Inhibitors Targeting the HemagglutininViruses, 2013
- Influenza Virus-Mediated Membrane Fusion: Determinants of Hemagglutinin Fusogenic Activity and Experimental Approaches for Assessing Virus FusionViruses, 2012
- Emerging cellular targets for influenza antiviral agentsTrends in Pharmacological Sciences, 2011
- CL-385319 inhibits H5N1 avian influenza A virus infection by blocking viral entryEuropean Journal of Pharmacology, 2011
- Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccinesProtein & Cell, 2010
- Oseltamivir-Ribavirin Combination Therapy for Highly Pathogenic H5N1 Influenza Virus Infection in MiceAntimicrobial Agents and Chemotherapy, 2008
- The CPSF30 Binding Site on the NS1A Protein of Influenza A Virus Is a Potential Antiviral TargetJournal of Virology, 2006